Targets › DNA
28 programs from 25 companies in 42 trials: 22 Phase 2, 14 Phase 3, 6 Phase 1; Oncology, Infectious disease; next expected readout Nov 2026.
Open in Phaseline: the race on DNA, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sun Yat-sen University | carboplatin DNA-alkylating platinum agent that forms covalent DNA adducts | DNA | Phase 3 | Retinoblastoma; Resectable Mucosal Melanoma | Mar 2027 |
| Henan Cancer Hospital | Carboplatin Platinum-based chemotherapy; DNA crosslinking agent | DNA | Phase 3 | Esophageal Squamous Cell Carcinoma; Esophageal Malignant Neoplasm Primary | Dec 2027 |
| SymBio Pharmaceuticals | Brincidofovir DNA polymerase inhibitor | DNA | Phase 3 | Adenovirus Infections; Progressive Multifocal Leukoencephalopathy | Jan 2028 |
| Fondazione Italiana Linfomi - ETS | Obinutuzumab-bendamustine (G-Benda) glycoengineered anti-CD20 monoclonal antibody combined with alkylating agent bendamustine | CD20, DNA | Phase 3 | Follicular Lymphoma | Jul 2028 |
| Fondazione Italiana Linfomi - ETS | Rituximab-bendamustine (R-Benda) anti-CD20 monoclonal antibody combined with alkylating agent bendamustine | CD20, DNA | Phase 3 | Follicular Lymphoma | Jul 2028 |
| Henan Cancer Hospital | Cisplatin DNA crosslinking agent | DNA | Phase 3 | Esophageal Squamous Cell Carcinoma | Dec 2028 |
| Vastra Gotaland Region | Melphalan Alkylating agent delivered via hepatic perfusion | DNA | Phase 3 | Uveal Melanoma | Dec 2028 |
| Binkui Li | Oxaliplatin Platinum-based chemotherapy (DNA cross-linking agent) | DNA | Phase 3 | Hepatocellular Carcinoma | May 2030 |
| Children's Oncology Group | Dactinomycin Antineoplastic antibiotic; DNA intercalating agent | DNA | Phase 3 | Embryonal Rhabdomyosarcoma; Stage I Mixed Cell Type Kidney Wilms Tumor; Rhabdomyosarcoma | Jun 2030 |
| Kyung Hee University Hospital at Gangdong | Oxaliplatin Platinum-based alkylating agent; DNA crosslinker | DNA | Phase 3 | Rectal Cancer | – |
| European Organisation for Research and Treatment of Cancer - EORTC | mechlorethamine hydrochloride Nitrogen mustard; alkylating agent | DNA | Phase 3 | Lymphoma | – |
| Memorial Sloan Kettering Cancer Center | Captisol Enabled Melphalan Nitrogen mustard alkylating agent (melphalan formulation with Captisol) | DNA | Phase 2 | Sarcoma; Multiple Myeloma; Lymphoma; Hematologic Malignancies | Nov 2026 |
| Shanghai Jiao Tong University School of Medicine | Satraplatin Platinum-based alkylating agent; forms DNA cross-links | DNA | Phase 2 | Prostate Cancer Patients | Dec 2026 |
| National Cancer Institute, Naples | Temozolomide Alkylating agent causing DNA methylation | DNA | Phase 2 | Lung Neuroendocrine Neoplasm | Dec 2026 |
| Hebei Medical University Fourth Hospital | Cisplatin Platinum-based alkylating agent; DNA cross-linker | DNA | Phase 2 | Esophageal Squamous Cell Carcinoma | Dec 2026 |
| The Second Affiliated Hospital of Fujian Medical University | Oxaliplatin Third-generation platinum agent causing DNA cross-linking | DNA | Phase 2 | Stomach Neoplasms | Dec 2026 |
| Shanghai Jiao Tong University School of Medicine | cisplatin DNA alkylating agent, platinum compound | DNA | Phase 2 | Neoplasm Neck | Jan 2027 |
| Tianjin Medical University General Hospital | Temozolomide Alkylating agent | DNA | Phase 2 | Glioblastoma, IDH-wildtype | Feb 2027 |
| Université de Sherbrooke | IA Carboplatin + IA Caelyx Carboplatin (platinum-based alkylating agent) combined with liposomal doxorubicin (anthrac | DNA | Phase 2 | Glioblastoma Multiforme | Apr 2027 |
| Changhai Hospital | Cisplatin Platinum-based alkylating agent that cross-links DNA strands | DNA | Phase 2 | Neoadjuvant Therapy | Aug 2027 |
| Shanghai Chest Hospital | Carboplatin Platinum-based alkylating agent; DNA crosslinking | DNA | Phase 2 | Non-squamous NSCLC | Dec 2027 |
| Fifth Affiliated Hospital, Sun Yat-Sen University | Temozolomide Alkylating agent | DNA | Phase 2 | Recurrent Glioblastoma | Dec 2027 |
| M.D. Anderson Cancer Center | Cisplatin Platinum-based DNA cross-linking agent | DNA | Phase 2 | Head and Neck Squamous Cell Carcinoma | Dec 2027 |
| Tianjin Medical University Cancer Institute and Hospital | Temozolomide Alkylating agent | DNA | Phase 2 | Neuroblastoma (NB) | Dec 2028 |
| Institut Curie | VP16, carboplatin Platinum-based alkylating agent + thermal laser therapy (chemothermotherapy) | DNA | Phase 2 | Retinoblastoma | Jan 2035 |
| Oslo University Hospital | Oxaliplatine DNA-crosslinking alkylating agent | DNA | Phase 2 | Pancreatic Cancer | – |
| Emory University | Temozolomide Alkylating agent | DNA | Phase 1 | Neuroblastoma | Dec 2026 |
| Haukeland University Hospital | Temozolomide DNA alkylating agent | DNA | Phase 1 | Glioblastoma | Dec 2026 |
Lymphoma (4) Retinoblastoma (4) Esophageal Squamous Cell Carcinoma (3) Sarcoma (2) Multiple Myeloma (2) Follicular Lymphoma (2) Glioblastoma Multiforme (1) Esophageal Malignant Neoplasm Primary (1) Hematologic Malignancies (1) Rectal Cancer (1) Prostate Cancer Patients (1) Glioblastoma (1)
small molecule (11), mixed (7), antibody (3), other (2), protein or peptide (2)
Henan Cancer Hospital (2) Shanghai Jiao Tong University School of Medicine (2) Fondazione Italiana Linfomi - ETS (2) Université de Sherbrooke (1) Memorial Sloan Kettering Cancer Center (1) Kyung Hee University Hospital at Gangdong (1) Haukeland University Hospital (1) Children's Oncology Group (1) Shanghai Chest Hospital (1) Sun Yat-sen University (1) Institut Curie (1) Tianjin Medical University Cancer Institute and Hospital (1) Oslo University Hospital (1) Vastra Gotaland Region (1) Hebei Medical University Fourth Hospital (1) Emory University (1) Tianjin Medical University General Hospital (1) The Second Affiliated Hospital of Fujian Medical University (1) European Organisation for Research and Treatment of Cancer - EORTC (1) M.D. Anderson Cancer Center (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.